Biogen Idec receives FDA approval for haemophilia A drug
Biogen Idec has received approval from the US Food and Drug Administration (FDA) for its Eloctate to control and prevent bleeding episodes, perioperative management, as well as routine prophylaxis in adults and children with haemophilia A.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Bleeding | Children | Food and Drug Administration (FDA) | Haemophilia | Hemophilia | Pharmaceuticals